Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Apatinib for Resectable Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nanchong Central Hospital
- Registration Number
- NCT03228043
- Locations
- 🇨🇳
Yunhong Tian, Nanchong, Sichuan, China
Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2017-07-21
- Target Recruit Count
- 189
- Registration Number
- NCT03224221
- Locations
- 🇨🇳
First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03213587
- Locations
- 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China
Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Hui ting Xu，MD
- Target Recruit Count
- 42
- Registration Number
- NCT03210064
- Locations
- 🇨🇳
Hui ting Xu, Wuhan, Hubei, China
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03201146
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03199677
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-06-20
- Target Recruit Count
- 120
- Registration Number
- NCT03193424
- Locations
- 🇨🇳
FirstAHZhengzhouU, Zhengzhou, Henan, China
Apatinib in Refractory Colorectal Cancer
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2020-01-14
- Target Recruit Count
- 54
- Registration Number
- NCT03190616
- Locations
- 🇨🇳
the second hospital of Changzhou city, Changzhou, Jiangsu, China
🇨🇳Nanjing 81 Hospital, Nanjing, Jiangsu, China
🇨🇳the first affiliated hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Registration Number
- NCT03190239
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, China
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 21
- Registration Number
- NCT03180476
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chendu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.